Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) Director Blake Borgeson sold 8,885 shares of the business’s stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $7.39, for a total transaction of $65,660.15. Following the completion of the sale, the director now owns 7,528,989 shares of […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating)’s share price was down 4.8% during mid-day trading on Thursday following insider selling activity. The stock traded as low as $9.05 and last traded at $9.39. Approximately 270,739 shares changed hands during trading, a decline of 82% from the average daily volume of 1,493,078 shares. The stock had […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 15,485 shares of the firm’s stock in a transaction on Tuesday, June 13th. The stock was sold at an average price of $9.98, for a total transaction of $154,540.30. Following the completion of the sale, the director now owns 7,525,262 shares in the company, […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $8.63, but opened at $9.00. Recursion Pharmaceuticals shares last traded at $9.18, with a volume of 293,828 shares changing hands. Wall Street Analysts Forecast Growth RXRX has been the topic of a […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 8,885 shares of the stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $8.79, for a total transaction of $78,099.15. Following the transaction, the director now owns 7,540,747 shares in the company, valued at […]